Success Metrics

Clinical Success Rate
80.0%

Based on 4 completed trials

Completion Rate
80%(4/5)
Active Trials
5(50%)
Results Posted
50%(2 trials)
Terminated
1(10%)

Phase Distribution

Ph phase_2
4
40%
Ph early_phase_1
1
10%
Ph phase_1
5
50%

Phase Distribution

6

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution10 total trials
Early Phase 1First-in-human
1(10.0%)
Phase 1Safety & dosage
5(50.0%)
Phase 2Efficacy & side effects
4(40.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

80.0%

4 of 5 finished

Non-Completion Rate

20.0%

1 ended early

Currently Active

5

trials recruiting

Total Trials

10

all time

Status Distribution
Active(5)
Completed(4)
Terminated(1)

Detailed Status

Completed4
Active, not recruiting3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
10
Active
5
Success Rate
80.0%
Most Advanced
Phase 2

Trials by Phase

Early Phase 11 (10.0%)
Phase 15 (50.0%)
Phase 24 (40.0%)

Trials by Status

terminated110%
completed440%
recruiting220%
active_not_recruiting330%

Recent Activity

5 active trials
Showing 5 of 10
recruitingphase_2

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

NCT07446322
recruitingphase_1

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

NCT07280377
active_not_recruitingphase_1

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

NCT05514990
active_not_recruitingphase_2

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

NCT04445844
active_not_recruitingphase_2

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

NCT04215146
View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials
NCT07446322Phase 2

FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer

Recruiting
NCT07280377Phase 1

A Study in Advanced or Metastatic Gastrointestinal Cancers Exploring Treatment Combinations With Pelareorep and Atezolizumab

Recruiting
NCT05514990Phase 1

Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

Active Not Recruiting
NCT04445844Phase 2

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study

Active Not Recruiting
NCT04215146Phase 2

A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study

Active Not Recruiting
NCT02101944Phase 1

Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

Completed
NCT05519059Phase 1

Pelareorep and Paclitaxel Injection in Chinese Patients With Advanced or Metastatic Breast Cancer

Completed
NCT03605719Phase 1

Dexamethasone, Carfilzomib, & Nivolumab With Pelareorep for Relapsed/Refractory Multiple Myeloma

Completed
NCT04102618Early Phase 1

A Window-of-opportunity Study of Pelareorep in Early Breast Cancer

Terminated
NCT01199263Phase 2

Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Completed

All 10 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
10